<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588406</url>
  </required_header>
  <id_info>
    <org_study_id>07.02.019</org_study_id>
    <nct_id>NCT00588406</nct_id>
  </id_info>
  <brief_title>Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.</brief_title>
  <official_title>Emergency Department (ED) Use of Nebulized Budesonide as an Adjunct to Standardized Therapy in Acutely Ill Adults With Refractory Asthma: a Randomized, Double-blinded, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jacobi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nassau University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED
      patients with refractory acute asthma helps improve forced expiratory volume at one second
      (FEV1) and decrease the need for hospitalization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized clinical trial studying the effect of nebulized budesonide (Pulmicort)
      in acutely ill adults presenting to the Emergency Department with severe asthma. Budesonide
      is an inhaled steroid FDA approved for the treatment of pediatric chronic asthma. ED entry
      criteria include hyporesponsiveness to nebulized beta-agonists and an FEV1&lt;50% predicted. The
      trial will evaluate the efficacy of multiple doses of nebulized budesonide as an adjunct to a
      highly regimented standardized treatment protocol; standard care consists of bronchodilators
      (beta-agonists/anticholinergics), systemic steroids, and intravenous magnesium sulfate (if
      the FEV1&lt;25% predicted). The primary efficacy endpoint will be the FEV1 4 hours after
      administration of the study intervention. An additional safety and efficacy endpoint will
      take place at 5 hours after study intervention. The treatments will be coupled with a
      protocol-defined assessment regimen, with endpoints measured before each treatment and on ED
      disposition (at 5 hours after study intervention).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 Percent Predicted</measure>
    <time_frame>4 hours post-randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide, 2mg, 4 doses, plus standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>2mg/dose by nebulizer, four doses over 3 hours</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Pulmicort Respules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuterol</intervention_name>
    <description>2.5mg/dose by nebulizer, 7 doses over 6 hours</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>P</arm_group_label>
    <other_name>proventil</other_name>
    <other_name>proair</other_name>
    <other_name>ventolin</other_name>
    <other_name>salbutamol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium bromide</intervention_name>
    <description>2.5 mg, one dose</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>P</arm_group_label>
    <other_name>Atrovent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>60mg PO</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>P</arm_group_label>
    <other_name>deltasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FEV1&lt;50% predicted after bronchodilator therapy, age 18-60, presenting to an emergency
             department with acute asthma

        Exclusion Criteria:

          -  other chronic lung disease, &gt;15 pack years smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Silverman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nassau University Medical Center</name>
      <address>
        <city>East Meadow</city>
        <state>New York</state>
        <zip>11554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>Queens</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2008</study_first_posted>
  <results_first_submitted>October 12, 2015</results_first_submitted>
  <results_first_submitted_qc>December 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2016</results_first_posted>
  <last_update_submitted>December 15, 2015</last_update_submitted>
  <last_update_submitted_qc>December 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Robert A Silverman</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>acute, emergency department</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Budesonide</title>
          <description>Budesonide, 2mg, 4 doses, plus standard care
Budesonide: 2mg/dose by nebulizer, four doses over 3 hours
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
        </group>
        <group group_id="P2">
          <title>Placob</title>
          <description>Placebo plus standard care
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Budesonide</title>
          <description>Budesonide, 2mg, 4 doses, plus standard care
Budesonide: 2mg/dose by nebulizer, four doses over 3 hours
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo plus standard care
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="11.4"/>
                    <measurement group_id="B2" value="42.6" spread="11.4"/>
                    <measurement group_id="B3" value="40" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume at one second (FEV1) % predicted</title>
          <units>percent predicted of FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="9.5"/>
                    <measurement group_id="B2" value="29" spread="8.1"/>
                    <measurement group_id="B3" value="29.2" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 Percent Predicted</title>
        <time_frame>4 hours post-randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide, 2mg, 4 doses, plus standard care
Budesonide: 2mg/dose by nebulizer, four doses over 3 hours
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus standard care
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Percent Predicted</title>
          <units>percent predicted of FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" spread="16.8"/>
                    <measurement group_id="O2" value="52.6" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalization</title>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Budesonide</title>
            <description>Budesonide, 2mg, 4 doses, plus standard care
Budesonide: 2mg/dose by nebulizer, four doses over 3 hours
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo plus standard care
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalization</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Budesonide</title>
          <description>Budesonide, 2mg, 4 doses, plus standard care
Budesonide: 2mg/dose by nebulizer, four doses over 3 hours
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo plus standard care
albuterol: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Ipratropium bromide: 2.5 mg, one dose
Prednisone: 60mg PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Silverman</name_or_title>
      <organization>North Shore Long Island Jewish Health System</organization>
      <phone>718-470-7501</phone>
      <email>rsilverman@nshs.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

